Area: Oncology
Location: Chicago, United States
Date: June 3 to June 7
Description:
ASCO Annual Meeting.
Metastatic urothelial carcinoma PD-L1 expression, Cancer Genome Atlas subtype, and mutational load as independent predictors of response to atezolizumab
Clinical trials - lung cancer, head and neck cancers - new ways, further developments of treatment, combinations
ASCO/ECCO Joint session: Value Based Care
CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab alone or with ipilimumab in advanced and metastatic gastric cancer
US: Progress in Myeloproliferative Neoplasms
Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab
Management of Acute Lymphoblastic Leukemia
Safety and antitumor activity of hypofractionated stereotactic irradiation with pembrolizumab and bevacizumab in patients with recurrent high grade gliomas: Preliminary result
Advances in the treatment of head and neck cancers - combination: radiation and immunotherapy
Breast Cancer-Triple Negative/Cytotoxics/Local Therapy - Breast cancer highlights of ASCO 2016
Novel agents in Non-Hodgkin Lymphoma, in CNS involvment, in Limited-Stage Hodgkin Lymphoma
Nivolumab ± ipilimumab in treatment of patients with metastatic colorectal cancer with and without high microsatellite instability: CheckMate-142 interim results
US: Trends, most important results at ASCO 2016 - Immunotherapy, checkpoint inhibitors, targeted therapies, brain tumor